07:00 , Sep 10, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: ATP-binding cassette sub-family G WHITE member 2 (ABCG2; MXR; BCRP1)

Cancer INDICATION: Brain cancer Cell and mouse studies suggest combining an ABCG2 inhibitor with topotecan could help treat pediatric brain cancer. Levels of ABCG2 were higher in brain cells from pediatric patients with medulloblastoma or in a...
07:00 , Mar 28, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Hyperuricemia/gout ATP-binding cassette sub-family G WHITE member 2 (ABCG2; MXR; BCRP1) In vitro studies identified small...
07:00 , Oct 22, 2012 |  BC Week In Review  |  Company News

Cyprotex, Sigma-Aldrich sales and marketing update

Sigma Aldrich's Sigma Life Science business granted Cyprotex a non-exclusive license to offer Sigma's transporter knockout cell lines for ADMET screening and safety studies. The assays were developed using CompoZr Zinc Finger Nuclease (ZFN) technology....
07:00 , Oct 25, 2010 |  BC Week In Review  |  Company News

Charles River, Transposagen Biopharmaceuticals Inc. sales and marketing update

Charles River received exclusive, worldwide rights to market and distribute Transposagen's TGEM Knockout Rat Models. The models include a rat line with a mutation in the p53 gene and a second line with a mutation...
07:00 , Sep 9, 2010 |  BC Innovations  |  Distillery Techniques

Technology: Drug delivery

Approach Summary Licensing status Publication and contact information Drug delivery Improving blood brain barrier (BBB) drug delivery with ATP-binding cassette sub-family G WHITE member 2 (ABCG2; MXR; BCRP1) inhibitors ...
07:00 , May 24, 2010 |  BC Week In Review  |  Company News

Optivia Biotechnology Inc. sales and marketing update

Optivia Biotechnology Inc., Menlo Park, Calif.   Business: ADMET   Optivia launched its OptiDDI Suite, a polarized mammalian cell assay panel for analyzing seven transporter-related drug-drug interactions (DDI) highlighted by FDA as most clinically relevant to transporter-related...
08:00 , Nov 23, 2009 |  BC Week In Review  |  Clinical News

Paloma preclinical data

In mice, low (5.4 mg/kg) and high (54 mg/kg) doses of Palmoid 529 penetrated the blood brain barrier (BBB) with a brain-to-plasma ratio of >1. The low dose was slightly affected by P glycoprotein...
07:00 , Jun 25, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Metabolic disease Metabolic disorders ATP-binding...
07:00 , May 14, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology ...
08:00 , Feb 12, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer ...